MedPath

A comparative study for efficacy and safety of insertion of ESM UBT(for prevention of PPH) with IM oxytocin 10 IU versuss only IM oxytocin 10 I

Phase 2
Conditions
Health Condition 1: O72- Postpartum hemorrhage
Registration Number
CTRI/2023/09/057173
Lead Sponsor
Dr D SANTHOSHI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Delivering viable babies with high-risk pregnancies who are prone to atonic PPH

Grand multipara

Hydramnios

Pregnancy-induced hypertension

Eclampsia

Gestational Diabetes mellitus

Prolonged labour

Abruption

Deranged coagulation profile

Fibroids

Anemia

Twin pregnancy

Exclusion Criteria

Patient with traumatic PPH

Adherent or retained placenta

Uterine rupture

Anomalous uterus

Suspected chorioamnionitis

Purulent infections in cervix, vagina or uterus.

Known advanced cervical cancer

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the blood loss in women in which Dr Burkes UBTwith I.M oxytocin was used to those in whom only I.M oxytocin is used. <br/ ><br>Timepoint: Measuring Blood loss immediately after inserting UBT post delivery & 48hrs after delivery <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To assess the safety & efficacy of UBT <br/ ><br>To study the adverse effects of using UBT <br/ ><br>To assess the need for surgical intervention <br/ ><br>To assess the need for uterotonic drugs <br/ ><br>Timepoint: 18months
© Copyright 2025. All Rights Reserved by MedPath